1. Home
  2. GNPX vs XAIR Comparison

GNPX vs XAIR Comparison

Compare GNPX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.55

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.40

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
XAIR
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
GNPX
XAIR
Price
$0.55
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
365.0K
240.3K
Earning Date
05-11-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,679,000.00
Revenue This Year
N/A
$122.00
Revenue Next Year
N/A
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
107.26
52 Week Low
$0.14
$0.33
52 Week High
$12.97
$3.78

Technical Indicators

Market Signals
Indicator
GNPX
XAIR
Relative Strength Index (RSI) 42.11 40.48
Support Level $0.42 $0.36
Resistance Level $2.12 $0.52
Average True Range (ATR) 0.05 0.05
MACD 0.02 -0.00
Stochastic Oscillator 33.74 23.48

Price Performance

Historical Comparison
GNPX
XAIR

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: